两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
多数的专家认为这得益于“无进展生存”，阿瓦斯丁已经被许多肿瘤学家作为“未贴签”药物用于治疗，足以完全通过审批。
Most scientific experts consider this benefit "progression-free survival," sufficient for full approval, and many oncologists have been using Avastin as an "off-label" drug for this purpose.
他指出，研究结果还表明，患者的一个子集可能表现出更显著的效应。这在无进展生存期（PFS）的结果中能明显地看出来。
The findings also suggest that a subset of patients may be achieving a more significant benefit. This is apparent in the results of PFS, he pointed out.
在确诊时的转化预示相对较好的预后，5年无进展生存率和总生存率分别达到66%和88%。
Transformation at the time of diagnosis portends a more favorable prognosis with 5-year PFS and OS rates of 66% and 88%, respectively.
目的：前列腺癌内分泌治疗后发现进展速度存在较大差异，为了改善其预后，本文探讨前列腺癌内分泌治疗后无进展生存期的影响因素。
This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.
即使无进展生存期的中位数看起来不相同，风险比是0.6。“因为存在一个重要的患者子集通过一个重要途径受益。”
Even though the median in PFS doesn't look different, the HR is 0.6 "because there is a significant patient subset who benefit in a significant way. ""
共同的初级终点指标为总生存率和无进展生存率。
Coprimary end points were rates of overall and progression-free survival.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
应用推荐